
Partner
Challenge
The people hired to make strategic decisions spent their time gathering data. Databases were thin on early and private companies, landscapes went stale within a week, and trackers were updated by hand.
Approach
Outcome
Each team brings its own questions to Studio. Landscapes get rerun when the field changes, and companies, assets, and vendors get checked before the first call.

Studio pulls every relevant drug, trial, deal, and company, then runs the analysis on top.
Pulled 1,180 active trials and their patient populations, then modeled how each readout shifts the standard of care. If the late-stage trials succeed, a new group of patients who stop responding appears, and few programs are built for them.
Matched each exhibitor to its pipeline, deals, and financing, then scored fit and readiness to partner. Six exhibitors were strong fits with unpartnered assets and no recent financing. Likely to deal soon.
Ranked 150 investors in UK biotech on portfolio assets in the team’s focus areas and how many pharma later licensed. The best fit wasn’t on the team’s list. The two firms it was weighing ranked fourth and eighth.
The price was nearly double what similar deals paid. But buyers have paid that much for drugs that reached market first, and this one is on track to be the first pill in its class.

The most reliable vendor wasn’t the busiest. None of its partnered programs was stopped for liver safety, against about one in seven across the field.

Five teams now do their research in Studio, so their time goes into the decisions instead of the data gathering.